Literature DB >> 17880835

Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.

Rodney A Appell1.   

Abstract

Pharmacological therapy is now considered a first-line treatment for men with moderate to severe lower urinary tract symptoms. Given the success of antimuscarinic agents, a-sympathetic blockers, and 5-a-reductase inhibitors in treating symptoms, the interest in combination therapy has grown. Despite this, large-scale trials to test the efficacy of such combination therapy are still lacking.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17880835     DOI: 10.1007/s11934-007-0033-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  11 in total

1.  Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.

Authors:  Claus G Roehrborn; Paul Abrams; Eric S Rovner; Steven A Kaplan; Sender Herschorn; Zhonghong Guan
Journal:  BJU Int       Date:  2006-05       Impact factor: 5.588

2.  Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology.

Authors:  R Gradini; M Realacci; A Ginepri; G Naso; C Santangelo; O Cela; P Sale; A Berardi; E Petrangeli; M Gallucci; F Di Silverio; M A Russo
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

3.  Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction.

Authors:  John P Mulhall; Patricia Guhring; Marilyn Parker; Carin Hopps
Journal:  J Sex Med       Date:  2006-07       Impact factor: 3.802

4.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

5.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Steven A Kaplan; Konstantin Walmsley; Alexis E Te
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

6.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

7.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

Authors:  John D McConnell; Claus G Roehrborn; Oliver M Bautista; Gerald L Andriole; Christopher M Dixon; John W Kusek; Herbert Lepor; Kevin T McVary; Leroy M Nyberg; Harry S Clarke; E David Crawford; Ananias Diokno; John P Foley; Harris E Foster; Stephen C Jacobs; Steven A Kaplan; Karl J Kreder; Michael M Lieber; M Scott Lucia; Gary J Miller; Mani Menon; Douglas F Milam; Joe W Ramsdell; Noah S Schenkman; Kevin M Slawin; Joseph A Smith
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

8.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

Authors:  Roger S Kirby; Claus Roehrborn; Peter Boyle; Georg Bartsch; Alain Jardin; Margaret M Cary; Michael Sweeney; Eric B Grossman
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

9.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Authors:  Claus G Roehrborn; Peter Boyle; J Curtis Nickel; Klaus Hoefner; Gerald Andriole
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

10.  The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.

Authors:  H Lepor; W O Williford; M J Barry; C Haakenson; K Jones
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.